A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Sitagliptin in Pediatric Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control

drug protocol number
MK0431-083
drug sponsor
MSD
drug study
Sitagliptin
drug trial site
NGHA-R
drug status
Ongoing
drug phase